http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11141432-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0acc7fd312a68983fb8b9d120043467e
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-999
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5158
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-876
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0638
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-208
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-713
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-352
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
filingDate 2017-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2021-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ebc7425198e7d9b469365fade6afc6c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d2e33d25175ecef0e731b4de46b7be5b
publicationDate 2021-10-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-11141432-B2
titleOfInvention Materials and methods for increasing immune responses
abstract Provided herein are materials and methods for treating a cancer and/or an infection in a mammal. One or more mitochondrial protein uncoupling protein 2 (UCP2) inhibitors can be administered to a mammal to enhance an immune response produced against an antigen (e.g., a tumor associated antigen or a pathogen associated antigen) present within the mammal.
priorityDate 2016-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010151517-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010278873-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008150388-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23830
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID166785016
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226420748
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID476585080
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394314
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395777
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID442424
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID643460
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394880
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23676745

Total number of triples: 46.